Search Videos and More
News
ASCO 2023 Highlights
Dana-Farber physician-scientists will share research and clinical advances at the 2023 Annual Meeting of the American Society of Clinical Oncologists (ASCO).
News
Study Sends Strong Signal Not to Sequence Immune Checkpoint Inhibitors in Advanced Kidney Cancer
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor treatment in metastatic renal cell carcinoma: primary PFS analysis from the Phase 3, randomized, open-label CONTACT-03 study
News
New Research from Dana-Farber Brigham Cancer Center and Memorial Sloan Kettering Cancer Center Finds that Radiation Can Be Safely Omitted in Select Patients with Locally Advanced Rectal Cancer
New data led by researchers at Dana-Farber Brigham Cancer Center and Memorial Sloan Kettering Cancer Center (MSK) and featured in the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting press program and simultaneously published in?The New England Journal of Medicine (NEJM)?and the Journal of Clinical Oncology today indicates that some patients with locally advanced rectal cancer with tumors that respond to chemotherapy can safely forego radiation before surgery.
News
Clinical Trial Points to Treatment Advances for Glioma Patients for First Time in Decades
In the phase 3 INDIGO clinical trial co-led by Dana-Farber Cancer Institute, vorasidenib significantly prolonged progression free survival and delayed radiation and chemotherapy for patients with Grade 2 IDH-mutant glioma.
Podcast
Season 2, Episode 6: Big Data, AI, and Cancer Research
As our universe of knowledge expands, sometimes incrementally and more often, exponentially, its new dimensions create new challenges. The more we know, the better our tools are, the more choices we have. And that's great, but it's hard to distill mountains of patient data, clinical trials, therapies, discoveries, and a boatload of externalities.
Podcast
Season 2, Episode 5: With a Little Help From My Friends: Combination Immunotherapy
If there is such a thing as a holy grail in cancer research, a secret spell or golden ring that can ward off any and all forms of the disease, it probably lives somewhere in the realm of immunotherapy.
News
Institute Research Shines at Society of Gynecologic Oncology Annual Meeting
Researchers in the Division of Gynecologic Oncology reported results from an array of clinical trials, gave an overview of trials currently under way, and presented promising findings from the lab.
News
Three-Drug Combination Slows Progression of Advanced Kidney Cancer
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute.
News
Immunotherapy – Targeted Drug Combination Improves Survival in Advanced Kidney Cancer
The data presented here align with the initial results of the primary analysis of the CLEAR trial. This supports the use of lenvatinib plus pembrolizumab as a standard-of-care first-line treatment for patients with renal cell carcinoma.
News
Seeking Signs of Synergy: The Origins of PARP and PI3K Inhibitors
Pairing multiple drugs together to synergistically destroy a patient's tumor has become a common approach to cancer treatment
News
New Clinical Tool for Clonal Hematopoiesis Identifies Patients at High Risk for Blood Cancer
A new clinical tool developed by a team of researchers led by the Dana-Farber Cancer Institute pinpoints which Clonal hematopoiesis patients are at highest risk for cancer progression.
Symposium
2023 ASPHO Conference Highlights
Review Dana-Farber Faculty presentations from the ASPHO 2023 conference.